Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus bevacizumab in advanced EGFR-mutated non-small cell lung cancer
2011-004481-15Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- May 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-free survival. Started May 2012; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-004481-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004481-15.